ArticleStem cells and cloning : advances and applications2010
Induced pluripotent stem cells: advances to applications.
Article in Stem cells and cloning : advances and applications, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The role and mechanism of NRG1/ErbB4 in inducing the differentiation of induced pluripotent stem cells into cardiomyocytes.BMC cardiovascular disorders · 2024Article
- Stem Cells in Domestic Animals: Applications in Health and Production.Animals : an open access journal from MDPI · 2022Article
- Current Status on Canine Foetal Fluid and Adnexa Derived Mesenchymal Stem Cells.Animals : an open access journal from MDPI · 2021Review
- Composite Nanoscaffolds Modified with Bio-ceramic Nanoparticles (Zn2SiO4) Prompted Osteogenic Differentiation of Human Induced Pluripotent Stem Cells.International journal of molecular and cellular medicine · 2019Article
- TGF-β1/CD105 signaling controls vascular network formation within growth factor sequestering hyaluronic acid hydrogels.PloS one · 2018Article
- Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-β against Lymph Node-Derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models.Cancer research and treatment · 2017Article
- Designing 3D Mesenchymal Stem Cell Sheets Merging Magnetic and Fluorescent Features: When Cell Sheet Technology Meets Image-Guided Cell Therapy.Theranostics · 2016Article
- [Research advances on gene therapy for hemophilia A].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- Comparison of different protocols for neural differentiation of human induced pluripotent stem cells.Molecular biology reports · 2014Article
- Ectodermal dysplasia associated with sickle cell disease.Case reports in dentistry · 2014Article
- Bioengineered skin substitutes: key elements and novel design for biomedical applications.International wound journal · 2013Review
- Article
- Identification of human embryonic progenitor cell targeting peptides using phage display.PloS one · 2013Article
- The science and ethics of induced pluripotency: what will become of embryonic stem cells?Mayo Clinic proceedings · 2011Article
- Generation of Induced Pluripotent Stem (iPS) Cells by Nuclear Reprogramming.Stem cells international · 2011Article
- Targeted gene therapy for the treatment of heart failure.The Canadian journal of cardiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Induced pluripotent stem cell (iPS) technology has enriched the armamentarium of regenerative medicine by introducing autologous pluripotent progenitor pools bioengineered from ordinary somatic tissue. Through nuclear reprogramming, patient-specific iPS cells have been derived and validated. Optimizing iPS-based methodology will ensure robust applications across discovery science, offering opportunities for the development of personalized diagnostics and targeted therapeutics. Here, we highlight the process of nuclear reprogramming of somatic tissues that, when forced to ectopically express stemness factors, are converted into bona fide pluripotent stem cells. Bioengineered stem cells acquire the genuine ability to generate replacement tissues for a wide-spectrum of diseased conditions, and have so far demonstrated therapeutic benefit upon transplantation in model systems of sickle cell anemia, Parkinson's disease, hemophilia A, and ischemic heart disease. The field of regenerative medicine is therefore primed to adopt and incorporate iPS cell-based advancements as a next generation stem cell platforms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.